CTOs on the Move


 
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.opiant.com
  • 233 Wilshire Boulevard Suite 280
    Santa Monica, CA USA 90401
  • Phone: 424.252.4756

Executives

Name Title Contact Details

Similar Companies

Your MedSource

Your MedSource is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osco Drug

Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Health

Alliance Health is an innovative technology company whose mission is to improve health outcomes, lower costs and foster a more consumer-centric healthcare industry. We own and operate the internet`s largest group of condition-specific social communities serving over 1.5 million registered members across a broad set of chronic health conditions. Each site leverages social and mobile elements to empower patients and caregivers with connections to supportive peers, personalized information, and relevant products and services. We also offer access to affordable prescription medications, either home-delivered, or through our pharmacy network.

Aphena Pharma Solutions New Jersey

Aphena Pharma Solutions New Jersey is a Whippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.